Spotlight on Cardiology

Credits: 0.25 CME
Sarcoidosis: Considerations in the Management of Refractory Disease - Comprehensive Management of Sarcoidosis
Divya Patel, DO
Vindico

Sarcoidosis: Considerations in the Management of Refractory Disease - Comprehensive Management of Sarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Intro video
  • Comprehensive Management of Sarcoidosis
    • Faculty: Dr. Patel and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Intro video
  • Comprehensive Management of Sarcoidosis
    • Faculty: Dr. Patel and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Cardiology Presentations

1.00 CME / CNE / CPE
AcademicCME
Advances in the Management of Acute and Chronic Hyperkalemia

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.25 CME / MOC
Vindico
Managing Cardiovascular Disease Risk in Women

Managing Cardiovascular Disease Risk in Women

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™ /
ABIM MOC
Released: September 30, 2020
Expires: September 29, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe traditional and female-predominant factors that contribute to CVD risk in women.
  • Outline available screening tools and guidelines to identify women with elevated CVD risk.
  • Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
  • Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
  • Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.

Activity Description

Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.

Agenda

Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC

Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Faculty

Activity Co-Chairs:

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ

Disclosure: No relevant financial relationships to disclose.


Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) MOC program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™ /
ABIM MOC
Released: September 30, 2020
Expires: September 29, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe traditional and female-predominant factors that contribute to CVD risk in women.
  • Outline available screening tools and guidelines to identify women with elevated CVD risk.
  • Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
  • Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
  • Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.

Activity Description

Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.

Agenda

Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC

Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Faculty

Activity Co-Chairs:

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ

Disclosure: No relevant financial relationships to disclose.


Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) MOC program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.50 CME
AcademicCME
Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events

Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)™ / 1.50 Hours of External CME Credits (European Board for Accreditation in Cardiology)
Released: July 24, 2020
Expires: July 23, 2021
90 minutes to complete

Accredited By

Program Overview

Heart disease continues to be the leading cause of mortality in Europe. Despite advances in prevention and therapy, each year cardiovascular disease (CVD) causes over 1.8 million deaths in the European Union (EU).  CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU, is the main cause of death in men in all but 12 countries of Europe, and is the main cause of death in women in all but two countries. Acute coronary syndromes (ACS) comprise a substantial portion of these grim statistics, and better care for ACS patients could improve clinical and economic outcomes in the EU.  While evidence-based society guidelines recommend aggressive dual antiplatelet therapy (DAPT) for such patients, contemporary practice data on both sides of the Atlantic indicate that DAPT is underutilized both early after an index MI and for evidence-grounded durations of therapy.  In addition, in 2019 new data were published that demand re-evaluation of oral antiplatelet drug choice and of the role of long-term aspirin therapy in secondary prevention of ACS.  Education of all stakeholders in ACS/MI care—particularly interventional cardiologists—about the guidelines and their basis, and about improving practice to reflect recommendations for care, especially around DAPT, can improve outcomes in ACS.

Target Audience

The target audience includes cardiologists (clinical and interventional) and other healthcare providers engaged in the care of ACS and its secondary prevention.

Agenda

  • Overview of Controversies in Secondary Prevention of ACS
  • The Foundational Role of Antiplatelet Therapy in Secondary Prevention of ACS
  • Risk Stratification for Secondary Ischemia vs Bleeding Complications With Antiplatelet Therapy
  • Is the Acetylsalicylic Acid Component of DAPT Required for the Duration?
  • What is the Clinical Impact of Antiplatelet Agent Choice in Secondary Prevention? An Analysis of ISAR-REACT 5

Learning Objectives

  • Describe the latest evidence-based guideline recommendations for secondary prevention of ACS/MI
  • Review the foundational role of antiplatelet therapy in secondary prevention of ACS/MI and manage their patients accordingly, with appropriate attention to risk benefit balance
  • Discuss the pertinent findings of recent trials of anti-platelet therapy in ACS, placing them in the context of prior data, established practice, and current guidelines

Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Faculty

Tobias Geisler, MD, MHBA, FESC
Consultant/Vice Head of Department
Department of Cardiology and Angiology
Eberhard-Karls-University
Tübingen, Germany


Philippe Gabriel Steg, MD
Professor of Cardiology
Université Paris-Diderot
Paris, France


Robert Storey, BSc, BM, DM
Professor of Cardiology
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Sheffield, United Kingdom


Uwe Zeymer, MD
Senior Cardiologist
Klinikum Ludwigshafen
Ludwigshafen, Germany


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; CSL Behring

Tobias Geisler, MD, MHBA, FESC
Consultant/Advisor: AstraZeneca Pharmaceuticals; Bayer AG
Grant/Research Support: Bayer AG; Bristol Myers Squibb Company
Speaker's Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Chiesi; Daiichi Sankyo Company Ltd.; Ferrer Pharma; Pfizer, Inc.

Philippe Gabriel Steg, MD
Grant/Research Support: Bayer AG; Sanofi; Servier Laboratories
Speaker's Bureau: Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Idorsia Pharmaceuticals Ltd.; Mylan Inc.; Novo Nordisk; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Regeneron Pharmaceuticals; Sanofi; Servier Laboratories

Robert Storey, BSc, BM, DM
Consultant/Advisor: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; GylCardial Diagnostics; Haemonetics Corporation; Portola Pharmaceuticals; Thromboserin Ltd
Grant/Research Support: AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Pfizer, Inc.
Speaker's Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Pfizer, Inc.

Uwe Zeymer, MD
Speaker's Bureau: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Boehringer Ingelheim International GmbH; Pfizer, Inc.; Ferrer Pharma; Novartis Pharmaceuticals Corporation; Sanofi

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation and Credit Designation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™.

Accreditation Council for Pharmacy EducationThe event “Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1.50 Hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 65% or better on the Post-Activity Test Questions and complete the Evaluation will receive a CME credit of completion.
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact admin@academiccme.com.

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)™ / 1.50 Hours of External CME Credits (European Board for Accreditation in Cardiology)
Released: July 24, 2020
Expires: July 23, 2021
90 minutes to complete

Accredited By

Program Overview

Heart disease continues to be the leading cause of mortality in Europe. Despite advances in prevention and therapy, each year cardiovascular disease (CVD) causes over 1.8 million deaths in the European Union (EU).  CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU, is the main cause of death in men in all but 12 countries of Europe, and is the main cause of death in women in all but two countries. Acute coronary syndromes (ACS) comprise a substantial portion of these grim statistics, and better care for ACS patients could improve clinical and economic outcomes in the EU.  While evidence-based society guidelines recommend aggressive dual antiplatelet therapy (DAPT) for such patients, contemporary practice data on both sides of the Atlantic indicate that DAPT is underutilized both early after an index MI and for evidence-grounded durations of therapy.  In addition, in 2019 new data were published that demand re-evaluation of oral antiplatelet drug choice and of the role of long-term aspirin therapy in secondary prevention of ACS.  Education of all stakeholders in ACS/MI care—particularly interventional cardiologists—about the guidelines and their basis, and about improving practice to reflect recommendations for care, especially around DAPT, can improve outcomes in ACS.

Target Audience

The target audience includes cardiologists (clinical and interventional) and other healthcare providers engaged in the care of ACS and its secondary prevention.

Agenda

  • Overview of Controversies in Secondary Prevention of ACS
  • The Foundational Role of Antiplatelet Therapy in Secondary Prevention of ACS
  • Risk Stratification for Secondary Ischemia vs Bleeding Complications With Antiplatelet Therapy
  • Is the Acetylsalicylic Acid Component of DAPT Required for the Duration?
  • What is the Clinical Impact of Antiplatelet Agent Choice in Secondary Prevention? An Analysis of ISAR-REACT 5

Learning Objectives

  • Describe the latest evidence-based guideline recommendations for secondary prevention of ACS/MI
  • Review the foundational role of antiplatelet therapy in secondary prevention of ACS/MI and manage their patients accordingly, with appropriate attention to risk benefit balance
  • Discuss the pertinent findings of recent trials of anti-platelet therapy in ACS, placing them in the context of prior data, established practice, and current guidelines

Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Faculty

Tobias Geisler, MD, MHBA, FESC
Consultant/Vice Head of Department
Department of Cardiology and Angiology
Eberhard-Karls-University
Tübingen, Germany


Philippe Gabriel Steg, MD
Professor of Cardiology
Université Paris-Diderot
Paris, France


Robert Storey, BSc, BM, DM
Professor of Cardiology
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Sheffield, United Kingdom


Uwe Zeymer, MD
Senior Cardiologist
Klinikum Ludwigshafen
Ludwigshafen, Germany


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; CSL Behring

Tobias Geisler, MD, MHBA, FESC
Consultant/Advisor: AstraZeneca Pharmaceuticals; Bayer AG
Grant/Research Support: Bayer AG; Bristol Myers Squibb Company
Speaker's Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Chiesi; Daiichi Sankyo Company Ltd.; Ferrer Pharma; Pfizer, Inc.

Philippe Gabriel Steg, MD
Grant/Research Support: Bayer AG; Sanofi; Servier Laboratories
Speaker's Bureau: Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Idorsia Pharmaceuticals Ltd.; Mylan Inc.; Novo Nordisk; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Regeneron Pharmaceuticals; Sanofi; Servier Laboratories

Robert Storey, BSc, BM, DM
Consultant/Advisor: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; GylCardial Diagnostics; Haemonetics Corporation; Portola Pharmaceuticals; Thromboserin Ltd
Grant/Research Support: AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Pfizer, Inc.
Speaker's Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Pfizer, Inc.

Uwe Zeymer, MD
Speaker's Bureau: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb Company; Boehringer Ingelheim International GmbH; Pfizer, Inc.; Ferrer Pharma; Novartis Pharmaceuticals Corporation; Sanofi

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation and Credit Designation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™.

Accreditation Council for Pharmacy EducationThe event “Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1.50 Hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 65% or better on the Post-Activity Test Questions and complete the Evaluation will receive a CME credit of completion.
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact admin@academiccme.com.

1.00 CME / CNE / CPE
American Heart Association
Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Hidden in Plain Sight: The Clinical Presentation of ATTR

Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Hidden in Plain Sight: The Clinical Presentation of ATTR

Start

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: July 15, 2020
Expires: July 14, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Describe the epidemiology and demography of wild-type and hereditary ATTR amyloidosis with review of special populations in whom the disease is more prevalent.
  2. Recognize the pathophysiology that leads to amyloid deposition in different organ systems, forming the basis for understanding treatment approaches.
  3. Describe the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys.
  4. Outline the diagnostic approach to follow when treating a patient with suspected ATTR amyloidosis with focus on imaging and scenarios that require invasive biopsy.

Activity Description

The purpose of this webinar is to discuss the epidemiology and demography of wild-type and hereditary ATTR amyloidosis, with a review of special populations in whom the disease is more prevalent, as well as insights into the pathophysiology that leads to amyloid deposition in different organ systems, such as the heart, nervous system, gastro-intestinal tract, and kidneys, forming the basis for understanding treatment approaches.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention project is to improve the care of patients with transthyretin amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Hidden in Plain Sight: The Clinical Presentation of ATTR
10 minutes – Q & A

Presenters

Frederick (Rick) L. Ruberg, MD
Director, Advanced Cardiovascular Imaging
Associate Professor of Medicine
Program Associate Director, Cardiovascular
Boston University School of Medicine
Boston, MA


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Family Medicine
University of Florida
Gainesville, FL

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant - Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 07/15/2020
TERMINATION DATE: 07/14/2023
LAST REVIEW DATE: July 2020
ACCREDITATION TERMS:
Joint Accreditation: 07/15/2020 – 07/14/2023
CAPCE: 07/15/2020 – 07/14/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:

View the content in its entirety.

Complete a post-test with a minimum score of 75%.

Complete a survey of your learning experience.

Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: July 15, 2020
Expires: July 14, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Describe the epidemiology and demography of wild-type and hereditary ATTR amyloidosis with review of special populations in whom the disease is more prevalent.
  2. Recognize the pathophysiology that leads to amyloid deposition in different organ systems, forming the basis for understanding treatment approaches.
  3. Describe the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys.
  4. Outline the diagnostic approach to follow when treating a patient with suspected ATTR amyloidosis with focus on imaging and scenarios that require invasive biopsy.

Activity Description

The purpose of this webinar is to discuss the epidemiology and demography of wild-type and hereditary ATTR amyloidosis, with a review of special populations in whom the disease is more prevalent, as well as insights into the pathophysiology that leads to amyloid deposition in different organ systems, such as the heart, nervous system, gastro-intestinal tract, and kidneys, forming the basis for understanding treatment approaches.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention project is to improve the care of patients with transthyretin amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Hidden in Plain Sight: The Clinical Presentation of ATTR
10 minutes – Q & A

Presenters

Frederick (Rick) L. Ruberg, MD
Director, Advanced Cardiovascular Imaging
Associate Professor of Medicine
Program Associate Director, Cardiovascular
Boston University School of Medicine
Boston, MA


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Family Medicine
University of Florida
Gainesville, FL

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant - Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 07/15/2020
TERMINATION DATE: 07/14/2023
LAST REVIEW DATE: July 2020
ACCREDITATION TERMS:
Joint Accreditation: 07/15/2020 – 07/14/2023
CAPCE: 07/15/2020 – 07/14/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:

View the content in its entirety.

Complete a post-test with a minimum score of 75%.

Complete a survey of your learning experience.

Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

0.25 CME
Vindico
Sarcoidosis: Considerations in the Management of Refractory Disease - Cardiac Sarcoidosis

Sarcoidosis: Considerations in the Management of Refractory Disease - Cardiac Sarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Cardiac Sarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Cardiac Sarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Sarcoidosis: Considerations in the Management of Refractory Disease - Comprehensive Management of Sarcoidosis

Sarcoidosis: Considerations in the Management of Refractory Disease - Comprehensive Management of Sarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Intro video
  • Comprehensive Management of Sarcoidosis
    • Faculty: Dr. Patel and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Intro video
  • Comprehensive Management of Sarcoidosis
    • Faculty: Dr. Patel and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Sarcoidosis: Considerations in the Management of Refractory Disease - Neurosarcoidosis

Sarcoidosis: Considerations in the Management of Refractory Disease - Neurosarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Neurosarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
  • Utilize available assessments to appropriately identify refractory or progressive disease.
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Neurosarcoidosis
    • Faculty: Dr. Culver and Dr. Patel

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Sarcoidosis: Considerations in the Management of Refractory Disease - Pulmonary Sarcoidosis

Sarcoidosis: Considerations in the Management of Refractory Disease - Pulmonary Sarcoidosis

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Pulmonary Sarcoidosis
    • Faculty: Dr. Culver and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 11, 2020
Expires: February 10, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
  • Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
  • Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.

Activity Description

Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.

Agenda

  • Pulmonary Sarcoidosis
    • Faculty: Dr. Culver and Dr. Marts

Faculty

Activity Chair

Daniel Culver, DO
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis Research, Mallinkrodt



Faculty

Lucian T. Marts, MD
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Disclosure:
Contracted Research: aTyr Pharma


Divya Patel, DO
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida

Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest question, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

CME for MIPS Improvement Activity

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages